CN1616014A - Chinese medicine composition for treating diabetes and its preparing method - Google Patents
Chinese medicine composition for treating diabetes and its preparing method Download PDFInfo
- Publication number
- CN1616014A CN1616014A CN 200410073959 CN200410073959A CN1616014A CN 1616014 A CN1616014 A CN 1616014A CN 200410073959 CN200410073959 CN 200410073959 CN 200410073959 A CN200410073959 A CN 200410073959A CN 1616014 A CN1616014 A CN 1616014A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- radix
- water
- fructus
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title description 12
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 31
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 415
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 127
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 126
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 94
- 239000000706 filtrate Substances 0.000 claims description 64
- 239000009636 Huang Qi Substances 0.000 claims description 57
- 239000008517 radix Trichosanthis Substances 0.000 claims description 56
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 55
- 238000002386 leaching Methods 0.000 claims description 50
- 238000002360 preparation method Methods 0.000 claims description 48
- 239000000843 powder Substances 0.000 claims description 44
- 239000013558 reference substance Substances 0.000 claims description 41
- 239000006228 supernatant Substances 0.000 claims description 38
- 239000008187 granular material Substances 0.000 claims description 35
- 239000007788 liquid Substances 0.000 claims description 35
- 239000000796 flavoring agent Substances 0.000 claims description 34
- 235000019634 flavors Nutrition 0.000 claims description 34
- 238000012360 testing method Methods 0.000 claims description 32
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 28
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 28
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 28
- 241000208340 Araliaceae Species 0.000 claims description 27
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 27
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 27
- 235000008434 ginseng Nutrition 0.000 claims description 27
- 238000005325 percolation Methods 0.000 claims description 27
- 235000005903 Dioscorea Nutrition 0.000 claims description 25
- 241000234273 Dioscorea Species 0.000 claims description 25
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 25
- 241000545442 Radix Species 0.000 claims description 25
- 235000004879 dioscorea Nutrition 0.000 claims description 25
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 25
- 229930182490 saponin Natural products 0.000 claims description 25
- 150000007949 saponins Chemical class 0.000 claims description 25
- 239000000047 product Substances 0.000 claims description 24
- 238000003556 assay Methods 0.000 claims description 23
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 21
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 21
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims description 21
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 21
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims description 21
- 238000005303 weighing Methods 0.000 claims description 21
- 239000012141 concentrate Substances 0.000 claims description 20
- 229920006395 saturated elastomer Polymers 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 14
- 239000000945 filler Substances 0.000 claims description 14
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 14
- 239000000377 silicon dioxide Substances 0.000 claims description 14
- 239000002552 dosage form Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- NSXFCODMXBYASQ-UHFFFAOYSA-N acetonitrile;oxolane;hydrate Chemical compound O.CC#N.C1CCOC1 NSXFCODMXBYASQ-UHFFFAOYSA-N 0.000 claims description 7
- 230000000274 adsorptive effect Effects 0.000 claims description 7
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 7
- 239000003480 eluent Substances 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 7
- 238000000105 evaporative light scattering detection Methods 0.000 claims description 7
- 239000003208 petroleum Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 241000416162 Astragalus gummifer Species 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 229920001615 Tragacanth Polymers 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 235000010408 potassium alginate Nutrition 0.000 claims description 3
- 239000000737 potassium alginate Substances 0.000 claims description 3
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 235000010487 tragacanth Nutrition 0.000 claims description 3
- 239000000196 tragacanth Substances 0.000 claims description 3
- 229940116362 tragacanth Drugs 0.000 claims description 3
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920000896 Ethulose Polymers 0.000 claims description 2
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 235000010410 calcium alginate Nutrition 0.000 claims description 2
- 239000000648 calcium alginate Substances 0.000 claims description 2
- 229960002681 calcium alginate Drugs 0.000 claims description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 2
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 239000000463 material Substances 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 3
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 241000218989 Trichosanthes Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 84
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 235000008504 concentrate Nutrition 0.000 description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 239000008103 glucose Substances 0.000 description 17
- 102000010909 Monoamine Oxidase Human genes 0.000 description 14
- 108010062431 Monoamine oxidase Proteins 0.000 description 14
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- -1 tincture Substances 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 102000019197 Superoxide Dismutase Human genes 0.000 description 10
- 108010012715 Superoxide dismutase Proteins 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000012856 packing Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 8
- 102100036721 Insulin receptor Human genes 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000004153 islets of langerhan Anatomy 0.000 description 7
- 238000000465 moulding Methods 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 5
- 229930182837 (R)-adrenaline Natural products 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 229960005139 epinephrine Drugs 0.000 description 5
- 108091008039 hormone receptors Proteins 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000003470 adrenal cortex hormone Substances 0.000 description 4
- 210000004100 adrenal gland Anatomy 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229940098465 tincture Drugs 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 229940087098 Oxidase inhibitor Drugs 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- UPPXMONNNGGKMB-UHFFFAOYSA-N 3-O-(alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranosyl)spergulagenic acid Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(CO)C(O)C2O)OC2C(C3C(C4C(C5(CCC6(CCC(C)(CC6C5=CC4)C(O)=O)C(O)=O)C)(C)CC3)(C)CC2)(C)C)OC(CO)C(O)C1O UPPXMONNNGGKMB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 208000002230 Diabetic coma Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000009400 out breeding Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The Chinese medicine composition for treating diabetes is prepared with 11 kinds of Chinese medicinal materials including ginsenoside, astragalus root, rehmannia root, ophiopogon root, trichosanthes root, etc., which are processed physically and chemically based their different physical and chemical properties separately. The present invention has unique recipe and obvious clinical diabetes treating effect.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition for the treatment of diabetes, is raw material with the Chinese crude drug specifically, and the Chinese patent medicine that is prepared from relates to the preparation method of this medicine simultaneously.
Background technology
Diabetes are a kind of complex diseases because of syndrome, be since in the body hormone of insulin deficit or antagonism insulin increase, or insulin can not be brought into normal play physiological action and a kind of syndrome of the glucose, protein and the lipid metabolic disorder that cause in target cell.It is characterized by the unusual rising of concentration of glucose and glucose in urine in the blood circulation, occur typical " three-many-one-little " symptom when blood glucose is too high, promptly repeatedly, polyuria, polyphagia and lose weight, and with fatigue and weak.Ketoacidosis, hypertonicity diabetic coma can take place in severe patient, and easily merge multiple infection.Along with the prolongation of the course of disease, its metabolism disorder can cause the chronic pathological changes of histoorgans such as eye, kidney, nerve, blood vessel and heart.If can not get timely, appropriate treatment, heart change, cerebrovascular disease, renal failure then take place, lose the sight of both eyes, situation such as lower limbs necrosis, become disable, lethal main cause.And onset diabetes rate height, the national sampling survey of 1995-1996, natural crowd's prevalence is up to 3.21% more than 20 years old, the whole nation 300,000 census of the population results in 1980, prevalence 4.21% more than 60 years old, single Jiangsu elderly population diabetes, impaired glucose tolerance prevalence then are respectively 14.49% and 10.21%, and no matter are developed country or developing country, and the sickness rate of diabetes is all rising year by year.
Mostly the medicine of clinical treatment 2 types is chemicals, widely used sulphanylureas, biguanides, other antidiabetic drugs and the adjuvant drug of being broadly divided into except that insulin at present.The sulfonylureas drugs for diabetes thing is topmost Remedies for diabetes.Can make that hepatic glycogen is synthetic to be increased,, surrounding tissue be strengthened to the sensitivity of insulin, the picked-up of glucose is increased, thereby reach the effect of blood sugar lowering again by the effect behind pair cell receptor or the receptor.But more easily cause untoward reaction such as hypoglycemia, granulocytopenia and cardiovascular disease.Biguanides antidiabetic drug heavy dose can cause digestive tract reaction, has the patient of pathological changes easily to cause lactic acidosis at lung, liver, kidney.Bring hidden danger for the extensive patients drug safety, for a change this situation for a long time, attempts treating with protocol in the plant clinically always.The traditional Chinese medical science is consistent to the cause of disease view of diabetes, thinks it mainly is that surfeit delicious food, overaction of the five emotions, chamber do not save, the dry and not enough Several Factors of natural endowment of calentura fire." Jilin Chinese medicine " 2003,23 (8): 14 report Liu Guang celebratings are treated 139 routine diabeticss with GUBEN JIANGTANG JIAONANG (being made by the Radix Astragali, Radix Ginseng, Fructus Corni, Radix Rehmanniae Preparata, Rhizoma Dioscoreae, Fructus Lycii, Fructus Schisandrae Chinensis, Os Draconis, Concha Ostreae, Radix Rehmanniae, Radix Trichosanthis, Radix Salviae Miltiorrhizae, Fructus Crataegi), result: produce effects 48 examples, effective 71 examples, invalid 20 examples, total effective rate 86%.
Summary of the invention
The objective of the invention is to provide a kind of Chinese medicine composition of effective treatment diabetes, another object of the present invention provides the preparation method of this Chinese medicine composition.
For achieving the above object, we have adopted following technical scheme:
Chinese medicine composition of the present invention is to be made by the raw material of following weight ratio:
Ginsenoside 4-8 weight portion Radix Astragali 80-150 weight portion Radix Rehmanniae 150-250 weight portion
Radix Ophiopogonis 45-80 weight portion Radix Trichosanthis 40-80 weight portion Fructus Lycii 80-160 weight portion
Fructus Schisandrae Chinensis 40-80 weight portion Rhizoma Dioscoreae 40-80 weight portion Fructus Rubi 20-50 weight portion
Poria 40-80 weight portion Rhizoma Alismatis 40-80 weight portion.
The weight ratio of the raw material of Chinese medicine composition of the present invention is preferably:
Radix Ginseng (stem and leaf) the saponin 6 weight portion Radixs Astragali 124 weight portion Radix Rehmanniae 186 weight portions
Radix Ophiopogonis 62 weight portion Radix Trichosanthis, 62 weight portion Fructus Lyciis, 124 weight portions
Fructus Schisandrae Chinensis 62 weight portion Rhizoma Dioscoreaes 62 weight portion Fructus Rubies 31 weight portions
Poria 62 weight portion Rhizoma Alismatis 62 weight portions.
Chinese medicine composition of the present invention can the preparation process preparation by routine become clinical acceptable various dosage forms as granule, tablet, pill, capsule, injection or oral liquid, tincture, suppository, mixture, powder, lotion, membrane, drop pill etc.
The dosage form of Chinese medicine composition of the present invention is preferably granule.
The every gram granule of granule of the present invention contains the ginsenoside Re: 0.1-10mg, every gram granule contains astragaloside 0.02-0.5mg.
The assay method of granule of the present invention is:
(1) ginsenoside Re's assay method is:
The preparation of reference substance solution: it is an amount of that precision takes by weighing ginsenoside Re's reference substance, adds methanol and make the solution that contains ginsenoside Re 0.4mg among every 1ml respectively, in contrast product solution;
The preparation of need testing solution: get this product, grind well, precision takes by weighing about 1 gram, add chloroform 20ml, water-bath refluxed 1 hour, filtered, discard chloroform, residue volatilizes solvent, and residue places same tool match conical flask together with filter paper, adds the saturated water 2ml moistening of n-butyl alcohol, the accurate adding with water-saturated n-butanol 50ml supersound extraction 30min, precision is measured supernatant 25ml, adds the ammonia solution triplication, shakes up, place, divide and get upper solution, evaporate to dryness, residue add methanol makes dissolving, quantitatively move in the 2ml measuring bottle, add methanol and be diluted to scale, shake up, promptly;
Chromatographic condition: with octadecylsilane chemically bonded silica is filler;
Volume ratio is that acetonitrile-0.05% phosphoric acid solution of 99:400 is a mobile phase; Detect wavelength 203nm; Algoscopy: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject hplc determination;
(2) assay method of astragaloside is:
Chromatographic condition: octadecylsilane chemically bonded silica is a filler; Evaporative light scattering detector;
Mobile phase: ratio is acetonitrile-water-oxolane of 33: 67: 4;
The preparation of reference substance solution: get the astragaloside reference substance and add methanol and make the solution that every 1ml contains 0.6mg, shake up, promptly;
The preparation of need testing solution: get this product, grind well, precision takes by weighing about 10 grams, add water 50ml dissolving, filter, filtrate is used defat with petroleum ether 2 times, (each 50ml) extracted in water saturated n-butyl alcohol jolting 4 times, merges n-butanol extracting liquid, extracts 2 times with ammonia solution, each 40ml discards ammonia solution, and the water 40ml saturated with n-butyl alcohol washes, discard water liquid, n-butyl alcohol liquid evaporate to dryness, residue add water 10mL makes dissolving, put coldly, pass through D
101Type macroporous adsorptive resins (interior through 1.5cm, long 18cm) is with water 100mL eluting, discard water liquid, reuse 40% ethanol 50ml eluting discards 40% ethanol elution, continue with 70% ethanol 100ml eluting, collect eluent, evaporate to dryness is with dissolve with methanol and be transferred in the 2ml measuring bottle, add methanol to scale, shake up, filter, promptly.Algoscopy: accurate respectively reference substance solution and each 20 μ l of need testing solution of drawing, inject hplc determination; The preparation method of the present composition is:
With Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, Poria four flavors are ground into fine powder, use warm water lixiviate 1-3 time Radix Ophiopogonis, each 0.5-3 hour, merge lixiviating solution, filter, filtrate is concentrated into the thick paste that relative density is 1.03-1.40, Fructus Schisandrae Chinensis 40-70% ethanol percolation, percolate reclaims ethanol, be concentrated into relative density and be about the 1.10-1.40 thick paste, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, the Rhizoma Alismatis water decocts 1-4 time, each 0.5-3 hour, merge decoction liquor, filter, it is 1.20 thick paste that filtrate is concentrated into relative density, put coldly, add ethanol and make and contain the alcohol amount and be 40%-80%, leave standstill, the leaching supernatant, reclaim ethanol, be concentrated into relative density 1.1-1.40, with above-mentioned stem and leaf of Radix Ginseng saponin, Rhizoma Dioscoreae is waited until four flavor fine powders, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge or are dry, add medicinal adjuvant routinely preparation process make clinical required dosage form.
Add suspending agent in the preparation as ethylhydroxyethylcellulose, chitin, methylcellulose, tragacanth, arabic gum, sodium alginate, potassium alginate, calcium alginate, hydroxyethyl-cellulose, hydroxypropyl cellulose, dextrin etc. in order to prevent that medicated powder layering or precipitation in liquid preparation or granule are everlasting.
Aforesaid preparation method can replace with purgation:
Use warm water lixiviate 1-3 time Radix Ophiopogonis, each 0.5-3 hour, merge lixiviating solution, filter, filtrate is concentrated into the thick paste that relative density is 1.03-1.40, Fructus Schisandrae Chinensis 40-70% ethanol, percolation, percolate reclaims ethanol, be concentrated into thick paste, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, the Poria water decocts 1-4 time, each 0.5-3 hour, merge decoction liquor, filter, it is 1.20 thick paste that filtrate is concentrated into relative density, put coldly, add ethanol and make and contain the alcohol amount and be 40%-80%, leave standstill, the leaching supernatant, reclaim ethanol, concentrate, with above-mentioned Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, extractum ginsenosides such as Rhizoma Dioscoreae merge or drying after again with the ginsenoside, add medicinal adjuvant routinely preparation process make clinical required dosage form.
Drug treatment of diabetic of the present invention has better curative effect.For showing medicine of the present invention to the treatment of diabetes effect, we have done a large amount of experimentatioies, below experimental example be used to further specify the present invention.
One, the present invention is to causing the influence of kidney of rats upper parathyrine hyperglycemia model
Type ii diabetes is common complaint among the elderly, frequently-occurring disease.Through clinical efficacy and experiment confirm, the present invention has certain hypoglycemic activity.This experiment is to quicken glycogen and steatolysis in the rat body with the adrenal gland, makes that concentration of glucose increases in the rat serum.Epinephrine can also suppress the intravital insulin of rat and discharge.Irritate the doses glucose to rat more simultaneously and quicken to cause hyperglycemia model.From experimental result, administration group and matched group relatively, the present invention has hypoglycemic activity clearly, we and GUBEN JIANGTANG JIAONANG are as positive controls simultaneously.
Material
Animal: the Wistar rat, male and female half and half, body weight are 230 ± 30g
Medicine: 1, the former powder of the present invention, for light brown to sepia, sweet in the mouth, little puckery.Drug effect dosage is respectively 50 times, 37.5 times, 25 times of clinical application amount).
2, GUBEN JIANGTANG JIAONANG, this pharmaceutical factory Laboratory Production.
Method and result:
Get 50 of rats, be divided into 5 groups at random, 10 every group.First group of negative matched group gives distilled water.Second group of positive matched group given GUBEN JIANGTANG JIAONANG.Third and fourth, five groups be respectively high, medium and low three dosage groups of the present invention, dosage is respectively 50 times, 37.5 times, 25 times of clinical application amount, the animal gastric infusion, medicine journey one month, after the last administration 1 hour, dosage injection epinephrine by 500 μ g/kg, cause adrenal gland's hyperglycemia model, irritate stomach with the dosage of glucose 1g/kg simultaneously, the foundation of acceleration model, adopt glucose oxidase method to measure empty stomach, the change of blood sugar of half an hour, 1 hour, 2 hours, 3 hours respectively, it the results are shown in Table 1.
Table 1 the present invention is to the influence of epinephrine moulding rat blood sugar content
Blood sugar content (mg%) X ± SD
1 hour 2 hours 3 hours half an hour on an empty stomach
82.8±18.3 233.5±65.3 247.6±57.1 144.0±67.6 95.9±10.3
Matched group
(n＝12) (n＝10) (n＝10) (n＝10) (n＝11)
94.1±31.8 195.6±39.1 220.0±39.3 150.4±57.7 90.7±21.0
Positive controls
(n＝10) (n＝11) (n＝10) (n＝11) (n＝10)
The high agent 97.9 of the present invention ± 23.4 244.6 ± 44.3 154.6 ± 35.4 101.9 ± 33.3 100.1 ± 14.3
Amount group (n=10) is (n=13) (n=12)
* *(n=13) (n=12)
Agent 95.9 among the present invention ± 22.9 236.8 ± 42.7 185.0 ± 42.1 109.2 ± 32.6 99.1 ± 10.1
Amount group (n=10) is (n=10) (n=10)
* *(n=9) (n=9)
The present invention hangs down agent 95.4 ± 22.5 224.1 ± 41.7 156.5 ± 48.0 113.8 ± 47.5 98.4 ± 10.4
Amount group (n=10) is (n=8) (n=10)
* *(n=9) (n=10)
***P＜0.001
Result and discussion:
The animal hyperglycemia model is a kind of method that increases with simulation irritability blood glucose due to the epinephrine, is equivalent to type ii diabetes patient's the post-stimulatory morbidity state of spiritual irritability of being grown up, so has certain clinical meaning.
GUBEN JIANGTANG JIAONANG can obviously reduce adrenal gland's disposition hyperglycemia and confirm for institute in the past.Therefore be selected to the positive control of this experiment as Chinese medicine, experimental result shows that the blood glucose response curve of GUBEN JIANGTANG JIAONANG group is low than negative control group, illustrates that this experimental result is believable.The blood glucose response curve that three dosage groups of the present invention are presented is low than negative control group also, especially with 1 hour difference highly significant (P＜0.01).
This experimental result shows that the present invention can suppress to increase reaction by the rat blood sugar due to the epinephrine preferably.
Two, the present invention is to the influence of mice alloxan diabetes model
Materials and methods:
1, medicine: alloxan moulding dosage 100mg/kg (being produced by Japan and light pharmaceuticals industry Co., Ltd.), all the other reagent are national market sale product.
2, medicine: powder of the present invention is a light brown, sweet in the mouth, little puckery.Drug dose is equivalent to 50 times, 37.5 times, 25 times of clinical adult's consumption respectively.
" GUBEN JIANGTANG JIAONANG " this pharmaceutical factory Laboratory Production.
3, animal: 50 of outbreeding system Kunming mouses, body weight 20 ± 2g.
4, grouping: pairing is divided equally five groups after measuring fasting glucose.Be grown up 50 times of consumption of first group of the present invention,
Be grown up 37.5 times of consumption of second group of the present invention, be grown up 25 times of consumption of the 3rd group of the present invention, the 4th group of GUBEN JIANGTANG JIAONANG, the 5th group of matched group gives distilled water (calculating by heavy dose of dosage).
5, pathology moulding and medication: animal ig administration, 1 time/day, continuous 7 days, ihr after the administration in seven days
By the tail vein injection alloxan, dosage 100mg/kg causes diabetes model, and in the 9th, 10,
14, blood sugar content is measured in difference rathole vena orbitalis posterior blood sampling from childhood in 18,22,24 days, simultaneously, and record animal dead number.
6, observation index: by aforementioned blood sampling day mensuration blood sugar content, after putting to death animal on the 24th day, examine pancreas at once, carry out A, B, cell tissue chemical staining, counting after fixing with BovwShi.
The result:
1, each treated animal survival condition
The injection alloxan after second day, each is organized blood glucose and obviously raises, death condition sees Table 1.Injection alloxan the 4th day (be the full course of treatment the 11st day), negative control group and GUBEN JIANGTANG JIAONANG group begin to occur dead, the negative control group general mortality rate was 70% when finished the course of treatment, GUBEN JIANGTANG JIAONANG group general mortality rate is 50%, high dose group of the present invention (adult consumption 50 times) and in dosage group (adult's consumption 37.5 times) general mortality rate be 20%, low dose group (adult consumption 25 times), it is dead not have 1 example.
2, each treated animal blood glucose situation
Each group blood glucose after moulding all has obvious rising, but total trend the present invention and GUBEN JIANGTANG JIAONANG group all are lower than matched group, and owing to matched group is fallen ill serious mice in viewing duration death, so mean blood glucose does not significantly raise in matched group.Even so; after moulding the 11st day; low dose group of the present invention, middle dosage group and GUBEN JIANGTANG JIAONANG group blood glucose and matched group compare, and still there were significant differences (P＜0.01), illustrate that the present invention has certain protection effect and hypoglycemic activity to alloxan moulding mice sugar disease.
3, islets of langerhans A, B cell pathology check result
Matched group, the islets of langerhans decreased number, form is irregular, a small amount of non-viable non-apoptotic cell fragment in the still visible islets of langerhans in the HE sheet, lymphocyte and histiocytic infiltrate, the A cytosis, the B cell reduces, and the B cell reduces in most of islets of langerhans.
Low dose group of the present invention, most of specimen islets of langerhans number is normal substantially, and (3 example) A cell and B cell proportion are normal in the part islets of langerhans, and other sections belong to moderate lesion, and the B cell has minimizing slightly, the A cytosis.
The dosage group belongs to the minor injury among the present invention, occurs the B cell in the part islets of langerhans and reduces the A cytosis.
High dose group of the present invention belongs to the minor injury, compares with positive controls, and lesion and damage obviously alleviates.
The GUBEN JIANGTANG JIAONANG group: 1 example is slight pathological changes, and all the other are the moderate pathological changes.
Above result shows that the present invention and GUBEN JIANGTANG JIAONANG group have certain protective role to alloxan moulding mouse islets B cell, and can reduce injury of pancreas degree and mouse death rate, and wherein medication group low dosage is the most obvious.
Three, the present invention is to the influence of lipid peroxide, monoamine oxidase, MAO, superoxide dismutase
Lipid peroxide (LPO) is in the chemical compound or the free unsaturated fatty acid peroxide that generated by the free radical effect, and maturity-onset diabetes is because dysbolismus (sugar and fat matter) causes the lipid peroxide increase, and can promote the development of diabetic complications.Therefore, measuring lipid peroxidation confrontation observation curative effect of the present invention is an important index.
Monoamine oxidase, MAO (Monoamine oxdase MAO) is that a class extensively is present in the monoamine oxidase, MAO class in the organism different tissues, and it has the oxidation deoxidation of the dissimilar monoamines of catalysis.The activity that someone finds monoamine oxidase, MAO in human brain blood and the platelet (WAO, EC, 1,4,1,3) with advancing age and showed increased, particularly since the seventies, substantial connection has been arranged owing to find the activity of aging course and some Senile disease and monoamine oxidase-B (MAO-B).People seek to use suitable oxidase inhibitor (MAOI) always and selectively suppress MAO--B to reach the purpose for the treatment of some Senile disease.
Superoxide dismutase (SOD) is to have one of main enzyme of eliminating the free radical effect, thereby reduces the level of lipid peroxide.Under the situation of some pathology, for example: radiation damage and aging can cause increasing of lipid peroxide when free radical increases.Therefore measure the metabolism situation that LPO in serum or the tissue and SOD can understand free radical.The blood vessel injury complication of diabetics is relevant with LPO and SOD, and the purpose of this experiment promptly is to understand the present invention's effect in this regard.
Materials and methods:
Use the LCR mouse inbred lines, body weight 25-30g, normal control group and positive right is established in the pairing grouping
According to group (GUBEN JIANGTANG JIAONANG), the present invention establishes high, medium and low three dosage groups.High dose (adult consumption 50 times), middle dosage (adult's consumption 37.5 times), low dosage (adult's consumption 25 times).Route of administration is irritated stomach, once a day, and sacrificed by exsanguination after two weeks of administration.Gather respectively that blood, brain, liver are MAO-B, LPO, SOD measures.
One, the mensuration of LPO, Hepar Mus or brain are made 10% tissue homogenate, get 0.1ml → add 8.1%SDS0.2ml; PH3.5,20%HACbufferl? 1.5ml; 0.8%TBA 1.5ml; 1 hour → water of the back 95 ℃ of water-baths of distilled water 0.5ml → stirring cooled off → adds n-butyl alcohol pyridine (15: 1) 3ml vibration back centrifugal (3000 rev/mins) 15 minutes → measure optical density value (O, D) under the 532nm wavelength towards test tube
Two, the mensuration of MAO-B, get → organize the cold PH7.4 of giving of 10 times of volumes that weighs → add, 0.2MP.B buffer grind to form homogenate → 1000g4 ℃ centrifugal 10 minutes → remove precipitation to get 4 ℃ of following 17000g of supernatant centrifugal 30 minutes → get precipitation to suspend with the 0.3ml0.2MP.B buffer and promptly get thick enzyme, adding 0.3ml80mM benzylamine in the test tube that has the ground lid; 2.4ml0.2MPH7.4P.B → 37 ℃ of water-baths vibration 3 hours → add the 60%PCAO0.3ml cessation reaction added 3 minutes → 3000 rev/mins of cyclohexane extraction 3ml vibrations centrifugal 10 minutes → get supernatant in 242nm wavelength photometry density (O.D value) up and down again.
Three, the mensuration of SOD:
Refer to that with reference to the auspicious trace in Dinke the blood superoxide dismutase rapid assay methods carries out.
Result and discussion:
The present invention is to the influence of mouse brain LPO
Group (n=8) X ± SD (0.D value) L P
Normal control 0.55 ± 0.046
Positive control (GUBEN JIANGTANG JIAONANG) 0.220 ± 0.064 11.84＜0.01
Low dose group 0.424 ± 0.034 6.23＜0.0 1
Middle dosage group 0.315 ± 0.073 7.70＜0.01
High dose group 0.250 ± 0.061 11.10＜0.01
The present invention is to the influence of Mouse Liver LPB
Group (n=8) X ± SD (0.D value) L P
Normal control 0.54 ± 0.035
Positive control (GUBEN JIANGTANG JIAONANG) 0.370 ± 0.064 6.59＜0.01
Low dose group 0.460 ± 0.083 2.51＜0.05
Middle dosage group 0.430 ± 0.075 3.76＜0.01
High dose group 0.355 ± 0.085 5.69＜0.01
The present invention is to the influence of mouse brain MAOB
Group (n=8) X ± SD (0.D value) L P
Normal control 0.466 ± 0.07
Positive control (GUBEN JIANGTANG JIAONANG) 0.213 ± 0.078 6.28＜0.01
Low dose group 0.332 ± 0.023 4.38＜0.01
Middle dosage group 0.315 ± 0.046 4.42＜0.01
High dose group 0.217 ± 0.055 7.23＜0.01
The present invention is to the influence of SOD in Mice
Group (n=8) X ± SD (0.D value) L P
Normal control 0.147 ± 0.013
Positive control (GUBEN JIANGTANG JIAONANG) 0.171 ± 0.011 3.99＜0.01
Low dose group 0.165 ± 0.014 2.66＜0.05
Middle dosage group 0.169 ± 0.010 3.79＜0.01
High dose group 0.170 ± 0.015 3.28＜0.01
Above-mentioned experimental result shows, the present invention has the effect of obvious reduction mouse brain, liver lipid peroxide, for the development that stops diabetic complications provides experimental basis, simultaneously the mouse brain monoamine oxidase-B there is tangible reduction effect, played the effect of oxidase inhibitor, superoxide dismutase has been had tangible potentiation.These effects of the present invention may provide experimental basis for clinical prevention diabetes and complication thereof.
Four, the present invention is to the influence of bone marrow cells in mice Insulin receptor INSR and adrenal cortical hormone receptor
Materials and methods
Animal
(1) gets pure lines ICL mice, 6 monthly ages, body weight (18 ± 2) g, male 10, divide equally 4 groups, I organizes negative contrast, and the II group is known drug positive control (GUBEN JIANGTANG JIAONANG), III group is low dose group of the present invention (adult's consumption 12.5 times), and the IV group is high dose group of the present invention (adult's consumption 25 times).
(2) get pure lines ICL mice, 18 monthly ages, body weight (35 ± 2) g, male 40, divide equally 4 groups, every group of medicining condition be with (1), more than each group be and measure Insulin receptor INSR and use.
(3) the Weistar rat is 20, and is male, and body weight (200 ± 10) g divides equally 4 groups, and each organizes the administration situation with (1), is used to measure adrenal cortical hormone receptor.
1, reagent:
(1) the single iodine atom of 1-14-A-insulin is provided by Sichuan Huaxi Medical Univ Isotope Lab.Activity 223 μ ci/mg, the non-marked insulin is the Sigma product.
(2) 6,7-[A] the Atdosterone activity is that 72ci/nnik (New England Nucleor Comp) non-marked Atdosterone (Slgma CO) produces.
3, assay method:
(1) Insulin receptor INSR is measured: get bone marrow cells in mice and make cell suspension according to a conventional method and make into 5-7 * 10
7The total liquid measure of/ml reaction tube is 1ml, and wherein the I insulin is 0.1ml, and the CPM value is amount adjustment on demand, and add 1000 times non-marked thing, hatched 2 hours 0 ℃ of ice-water bath stopped reaction for 22 ℃, put 49 fiber type filter membrane sucking filtration, clean rearmounted Fi2003 type immunity enumerator, measure CPM value and calculating.
CV 2.44 also draws Scatchard Plot, asks with [I] insulin 20nM to 20nM and gets 7 points, and the result has obvious saturated phenomenon, and Scatchard Plot result of calculation sees Table 1.Measure respectively 6 monthly ages and 18 the monthly age mice medullary cell Insulin receptor INSR number (getting one point method 10nM) the results are shown in Table II.
(2) adrenal cortical hormone receptor is measured: behind the rat anesthesia with cold buffer liquid A (20nM Na-Phosphate PH7.4 1mM disodium EDTA 2mM 2-hydroxyethymercaptane and10%giycerol (Wt/Vol) heart perfusion, dehematize.Operation in 0 ℃ of cold house, get brain, weigh, add the 2ml buffer A, use glass homogenizer homogenate, centrifugal 85000 * 9 * 45min gets supernatant homogenate and measures protein content with the Lowryis method, and Dexamethasone gets 100 times of non-marked thing competitions of 6 points (0.5nM-10nM), with the hydroxyapatite is separating medium, centrifugal 10000 * g 10min gets supernatant and adds mensuration CPM in the scintillation solution, and makes Schathard Plot, the results are shown in Table III.
Result and discussion:
1, the present invention can make 18 monthly ages bone marrow cells in mice Insulin receptor INSR numbers rise, but 6 monthly ages were not had effect, and aged Mus Insulin receptor INSR number has with the gesture that increases age and descend, so the present invention plays restitution.
2, the present invention can disturb adrenal cortical hormone receptor, makes it adhesion and descends, and Bamx reduces, and this also is favourable for preventing and treating diabetes.
Above result shows that old Mus that the present invention is used for Insulin receptor INSR hypofunction state can make it receptor binding capacity and raise, and therefore, the present invention can be used as insulin receptor regulator and takes an entrance examination in clinical.
Table II the present invention is to the effect of bone marrow cells in mice insulin not of the same age
(one point method 10nM) P divides into groups to be counted out
Negative control 693 ± 392
Positive control 839 ± 198＞0.05
6 monthly ages
The present invention's (low) 910 ± 466＞0.05
The present invention's (height) 899 ± 446＞0.05
Negative control 383 ± 230
Positive control 1027 ± 441＜0.01
18 monthly ages
The present invention's (low) 1130 ± 430＜0.01
The present invention's (height) 1240 ± 340＜0.01
Table III the present invention is to the effect of adrenal gland's sebum hormone receptor
Group r kd (m) Bmax fmol mg prot
I II I II I II
1.1×
Negative control 0.89 0.95 12 * 10 289 110
10
Positive control 0.87 0.85 1.1 3.1 130 102
The present invention's (low) 0.88 0.87 1.0 2.9 120 100
The present invention's (height) 0.87 0.86 0.9 2.1 110 96
I glucocorticoid receptor (GR) II mineralcorticoid receptor
Five, the present invention is to the influence of human body embryo lung diploid fibroblastic growth and PAS reaction
Materials and methods:
One, cell culture human embryonic lung fibroblast (2BS cell) is provided by Beijing Biological Product Inst., and the life-span of going down to posterity was 55 ± 10 generations.40 ages in generation of recovery human embryonic lung fibroblast from liquid nitrogen are with the EagleMEM culture fluid that contains 10% calf serum, 10%NaHCO
3, accent PH is 7.2-7.4, adds the 2ml-glutamine, 37 ℃ of incubations, treat that cell growth merges into monolayer after, with 0.25% trypsinization 2 minutes, abandon pancreatin and add culture fluid piping and druming and make cell suspension, going down to posterity to cultivate with 1: 2 ratio is equipped with experiment usefulness.
Two, the preparation of medicine: the present invention gets 10g and is dissolved in the 200ml redistilled water, through magnetic agitation 24 hours, filtering is dissolved particles not, filtered solution adds the MEM culture medium dry powder, the G6 filter sucking filtration sterilization of dissolving back, furnishing contains 10% calf serum, PH=7.2, filtered solution is a water-soluble portion of the present invention, and original liquid concentration is 50mg/ml.
Three, method and grouping
(1) acute toxicity testing get growth conditions good 40 age in generation 2BS cell number bottle, through 0.25% trypsinization, abandon pancreatin and add 10ml culture fluid piping and druming, be prepared into cell suspension, through cell counting, being diluted to cell concentration is 200,000/ml suspension, and getting 30 bottles of floor spaces is 13.8cm
2Inoculation bottle, every bottle graft kind 1ml cell suspension, 3ml contains the medicine culture medium, 3 bottles of matched groups, 3 bottles totally 33 bottles of each concentration of dosing group, the dosing group is initial concentration with 37.5mg/ml, below each concentration all by the dilution of 1: 0: 7 ratio, through 37 ℃ of incubations 4 hours, cell counting, gained result machine as calculated handles, and obtains the median effective dose (EDx) of medicine pair cell card wall rate influence.
(2) the present invention is to all same acute toxicity testing of the preparation of 2BS cell growth inhibition test, cell culture, cell suspension, this experiment is the present invention's first dosage to the 2BS cell growth inhibition test with the concentration that does not influence cell card wall rate in the toxicity test, concentration is 1050 μ g/ml, following concentration was by ratio dilution in 1: 0.5, and getting 24 bottles of floor spaces is 13.8cm
2Little square vase, 3 bottles is one group, one group of contrast, each group of experiment all adds the 1ml cell, and PAS reacts and descends in the cell, has illustrated that synthetic polysaccharide ability reduces or the catabolism enhancing in the cell, from this result of experiment, the present invention can significantly increase late content for polysaccharide in the cell, and this is that this useful experiment also shows regulating aspect the carbohydrate metabolism body, and the present invention can directly make a difference to carbohydrate metabolism at cellular level.This can confirm the effect of Insulin receptor INSR in integral level mutually in conjunction with preamble the present invention.
Following embodiment is further openly the present invention, need to prove that these embodiment only for optimal way of the present invention, do not limit the scope of protection of present invention.
Embodiment 1
Ginsenoside's 6 weight portion Radixs Astragali 124 weight portion Radix Rehmanniae 186 weight portions
Radix Ophiopogonis 62 weight portion Radix Trichosanthis, 62 weight portion Fructus Lyciis, 124 weight portions
Fructus Schisandrae Chinensis 62 weight portion Rhizoma Dioscoreaes 62 weight portion Fructus Rubies 31 weight portions
Poria 62 weight portion Rhizoma Alismatis 62 weight portions.
Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, Poria four flavors are ground into fine powder, soak clearly secondary with warm water Radix Ophiopogonis, each 2 hours, merge leaching, it is the thick paste of 1.30 (55-60 ℃) that filtrate concentrates the back relative density, Fructus Schisandrae Chinensis 50% ethanol, percolation, percolate reclaims ethanol, and being concentrated into relative density is 1.30 (55-60 ℃) thick paste, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, the Rhizoma Alismatis water decocts secondary, each 2 hours, collecting decoction, filter, filtrate is concentrated into the thick paste that relative density is 1.20 (55-60 ℃), puts coldly, adds ethanol and makes that to contain the alcohol amount be 60%, leave standstill, the leaching supernatant, reclaim ethanol, be concentrated into relative density 1.30 (55-60 ℃), above-mentioned stem and leaf of Radix Ginseng saponin, Rhizoma Dioscoreae is waited until four flavor fine powders, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge, mixing or drying, mixing, adding carboxycellulose sodium is an amount of, granulates, dry granulate, packing promptly.
Assay method is:
(1) ginsenoside Re's assay method is:
The preparation of reference substance solution: it is an amount of that precision takes by weighing ginsenoside Re's reference substance, adds methanol and make the solution that contains ginsenoside Re 0.4mg among every 1ml respectively, in contrast product solution;
The preparation of need testing solution: get this product, grind well, precision takes by weighing about 1 gram, add chloroform 20ml, water-bath refluxed 1 hour, filtered, discard chloroform, residue volatilizes solvent, and residue places same tool match conical flask together with filter paper, adds the saturated water 2ml moistening of n-butyl alcohol, the accurate adding with water-saturated n-butanol 50ml supersound extraction 30min, precision is measured supernatant 25ml, adds the ammonia solution triplication, shakes up, place, divide and get upper solution, evaporate to dryness, residue add methanol makes dissolving, quantitatively move in the 2ml measuring bottle, add methanol and be diluted to scale, shake up, promptly;
Chromatographic condition: with octadecylsilane chemically bonded silica is filler;
Volume ratio is that 99: 400 acetonitrile-0.05% phosphoric acid solution is a mobile phase; Detect wavelength 203nm; Algoscopy: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject the every gram granule of hplc determination and contain ginsenoside Re 0.1mg.
(2) assay method of astragaloside is:
Chromatographic condition: octadecylsilane chemically bonded silica is a filler; Evaporative light scattering detector;
Mobile phase: ratio is acetonitrile-water-oxolane of 33: 67: 4;
The preparation of reference substance solution: get the astragaloside reference substance and add methanol and make the solution that every 1ml contains 0.6mg, shake up, promptly;
The preparation of need testing solution: get this product, grind well, precision takes by weighing about 10 grams, add water 50ml dissolving, filter, filtrate is used defat with petroleum ether 2 times, (each 50ml) extracted in water saturated n-butyl alcohol jolting 4 times, merges n-butanol extracting liquid, extracts 2 times with ammonia solution, each 40ml discards ammonia solution, and the water 40ml saturated with n-butyl alcohol washes, discard water liquid, n-butyl alcohol liquid evaporate to dryness, residue add water 10mL makes dissolving, put coldly, pass through D
101Type macroporous adsorptive resins (interior through 1.5cm, long 18cm) is with water 100mL eluting, discard water liquid, reuse 40% ethanol 50ml eluting discards 40% ethanol elution, continue with 70% ethanol 100ml eluting, collect eluent, evaporate to dryness is with dissolve with methanol and be transferred in the 2ml measuring bottle, add methanol to scale, shake up, filter, promptly.
Algoscopy: accurate respectively reference substance solution 5 μ l, the 10 μ l of drawing, each 20 μ l of need testing solution inject hplc determination
Every gram granule contains astragaloside 0.02mg.
Embodiment 2
Ginsenoside's 4 weight portion Radixs Astragali 150 weight portion Radix Rehmanniae 250 weight portions
Radix Ophiopogonis 80 weight portion Radix Trichosanthis, 80 weight portion Fructus Lyciis, 160 weight portions
Fructus Schisandrae Chinensis 80 weight portion Rhizoma Dioscoreaes 80 weight portion Fructus Rubies 50 weight portions
Poria 80 weight portion Rhizoma Alismatis 80 weight portions
With Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, Poria four flavors are ground into fine powder, soak clearly 1 time with warm water Radix Ophiopogonis, each 3 hours, merge leaching, it is the thick paste of 1.30 (55-60 ℃) that filtrate concentrates the back relative density, Fructus Schisandrae Chinensis 70% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.30 (55-60 ℃) thick paste, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, the Rhizoma Alismatis water decocts 2 times, each 2 hours, collecting decoction, filter, filtrate is concentrated into the thick paste that relative density is 1.20 (55-60 ℃), puts cold, add ethanol and make that to contain the alcohol amount be 60%, leave standstill, the leaching supernatant reclaims ethanol, is concentrated into relative density 1.30 (55-60 ℃), with above-mentioned stem and leaf of Radix Ginseng saponin, Rhizoma Dioscoreae is waited until four flavor fine powders, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge or are dry, add medicinal lactose, the an amount of dry granulation of protein sugar, packing, both.
Assay method is:
(1) ginsenoside Re's assay method is:
The preparation of reference substance solution: it is an amount of that precision takes by weighing ginsenoside Re's reference substance, adds methanol and make the solution that contains ginsenoside Re 0.4mg among every 1ml respectively, in contrast product solution;
The preparation of need testing solution: get this product, grind well, precision takes by weighing about 1 gram, add chloroform 20ml, water-bath refluxed 1 hour, filtered, discard chloroform, residue volatilizes solvent, and residue places same tool match conical flask together with filter paper, adds the saturated water 2ml moistening of n-butyl alcohol, the accurate adding with water-saturated n-butanol 50ml supersound extraction 30min, precision is measured supernatant 25ml, adds the ammonia solution triplication, shakes up, place, divide and get upper solution, evaporate to dryness, residue add methanol makes dissolving, quantitatively move in the 2ml measuring bottle, add methanol and be diluted to scale, shake up, promptly;
Chromatographic condition: with octadecylsilane chemically bonded silica is filler;
Volume ratio is that 99: 400 acetonitrile-0.05% phosphoric acid solution is a mobile phase; Detect wavelength 203nm; Algoscopy: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject the every gram granule of hplc determination and contain ginsenoside Re 1.0mg.
(2) assay method of astragaloside is:
Chromatographic condition: octadecylsilane chemically bonded silica is a filler; Evaporative light scattering detector;
Mobile phase: ratio is acetonitrile-water-oxolane of 33: 67: 4;
The preparation of reference substance solution: get the astragaloside reference substance and add methanol and make the solution that every 1ml contains 0.6mg, shake up, promptly;
The preparation of need testing solution: get this product, grind well, precision takes by weighing about 10 grams, add water 50ml dissolving, filter, filtrate is used defat with petroleum ether 2 times, (each 50ml) extracted in water saturated n-butyl alcohol jolting 4 times, merges n-butanol extracting liquid, extracts 2 times with ammonia solution, each 40ml discards ammonia solution, and the water 40ml saturated with n-butyl alcohol washes, discard water liquid, n-butyl alcohol liquid evaporate to dryness, residue add water 10mL makes dissolving, put coldly, pass through D
101Type macroporous adsorptive resins (interior through 1.5cm, long 18cm) is with water 100mL eluting, discard water liquid, reuse 40% ethanol 50ml eluting discards 40% ethanol elution, continue with 70% ethanol 100ml eluting, collect eluent, evaporate to dryness is with dissolve with methanol and be transferred in the 2ml measuring bottle, add methanol to scale, shake up, filter, promptly.
Algoscopy: accurate respectively reference substance solution 5 μ l, the 10 μ l of drawing, each 20 μ l of need testing solution inject hplc determination
Every gram granule contains astragaloside 0.1mg.
Embodiment 3
Ginsenoside's 8 weight portion Radixs Astragali 80 weight portion Radix Rehmanniae 250 weight portions
Radix Ophiopogonis 80 weight portion Radix Trichosanthis, 80 weight portion Fructus Lyciis, 160 weight portions
Fructus Schisandrae Chinensis 80 weight portion Rhizoma Dioscoreaes 80 weight portion Fructus Rubies 50 weight portions
Poria 80 weight portion Rhizoma Alismatis 80 weight portions
With Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, Poria four flavors are ground into fine powder, soak clearly 1 time with warm water Radix Ophiopogonis, each 2 hours, merge leaching, it is the thick paste of 1.10 (55-60 ℃) that filtrate concentrates the back relative density, Fructus Schisandrae Chinensis 50% ethanol, percolation, percolate reclaims ethanol, and being concentrated into relative density is 1.30 (55-60 ℃) thick paste, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, the Rhizoma Alismatis water decocts 2 times, each 2 hours, collecting decoction, filter, filtrate is concentrated into the thick paste that relative density is 1.20 (55-60 ℃), puts coldly, adds ethanol and makes that to contain the alcohol amount be 70%, leave standstill, the leaching supernatant, reclaim ethanol, be concentrated into relative density 1.30 (55-60 ℃), above-mentioned stem and leaf of Radix Ginseng saponin, Rhizoma Dioscoreae is waited until four flavor fine powders, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge, mixing or drying, it is an amount of to add medicinal caramel, and mixed pelletization is encapsulated, packing, promptly.
Embodiment 4
Ginsenoside's 8 weight portion Radixs Astragali 150 weight portion Radix Rehmanniae 150 weight portions
Radix Ophiopogonis 80 weight portion Radix Trichosanthis, 80 weight portion Fructus Lyciis, 160 weight portions
Fructus Schisandrae Chinensis 80 weight portion Rhizoma Dioscoreaes 80 weight portion Fructus Rubies 50 weight portions
Poria 80 weight portion Rhizoma Alismatis 80 weight portions
With Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, Poria four flavors are ground into fine powder, soak clearly 2 time with warm water Radix Ophiopogonis, each 2 hours, merge leaching, it is the thick paste of 1.20 (55-60 ℃) that filtrate concentrates the back relative density, Fructus Schisandrae Chinensis 60% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.30 (55-60 ℃) thick paste, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, the Rhizoma Alismatis water decocts 3 times, each 1 hour, collecting decoction, filter, filtrate is concentrated into the thick paste that relative density is 1.20 (55-60 ℃), puts cold, add ethanol and make that to contain the alcohol amount be 75%, leave standstill, the leaching supernatant reclaims ethanol, is concentrated into relative density 1.30 (55-60 ℃), with above-mentioned stem and leaf of Radix Ginseng saponin, Rhizoma Dioscoreae is waited until four flavor fine powders, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge or are dry, add appropriate amount of starch, the general ball of making promptly gets pill.
Embodiment 5
Ginsenoside's 8 weight portion Radixs Astragali 150 weight portion Radix Rehmanniae 250 weight portions
Radix Ophiopogonis 45 weight portion Radix Trichosanthis, 80 weight portion Fructus Lyciis, 160 weight portions
Fructus Schisandrae Chinensis 80 weight portion Rhizoma Dioscoreaes 80 weight portion Fructus Rubies 50 weight portions
Poria 80 weight portion Rhizoma Alismatis 80 weight portions
Soak clearly 1 time with warm water Radix Ophiopogonis, each 3 hours, merge leaching, it is the thick paste of 1.10 (55-60 ℃) that filtrate concentrates the back relative density, Fructus Schisandrae Chinensis 50% ethanol, percolation, percolate reclaims ethanol, and being concentrated into relative density is 1.30 (55-60 ℃) thick paste, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, the Poria water decocts 2 times, each 2 hours, collecting decoction, filter, filtrate is concentrated into the thick paste that relative density is 1.20 (55-60 ℃), puts cold, add ethanol and make that to contain the alcohol amount be 70%, leave standstill, the leaching supernatant reclaims ethanol, is concentrated into relative density 1.30 (55-60 ℃), with above-mentioned Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge, the stem and leaf of Radix Ginseng saponin dissolve with ethanol, the ethanol of adding normal concentration stirs, filter, promptly get tincture.
Embodiment 6
Ginsenoside's 8 weight portion Radixs Astragali 150 weight portion Radix Rehmanniae 250 weight portions
Radix Ophiopogonis 80 weight portion Radix Trichosanthis, 40 weight portion Fructus Lyciis, 160 weight portions
Fructus Schisandrae Chinensis 80 weight portion Rhizoma Dioscoreaes 80 weight portion Fructus Rubies 50 weight portions
Poria 80 weight portion Rhizoma Alismatis 80 weight portions
With Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, Poria four flavors are ground into fine powder, soak clearly 3 time with warm water Radix Ophiopogonis, each 1 hour, merge leaching, it is the thick paste of 1.20 (55-60 ℃) that filtrate concentrates the back relative density, Fructus Schisandrae Chinensis 50% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.30 (55-60 ℃) thick paste, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, the Rhizoma Alismatis water decocts 3 times, and each 1 hour, collecting decoction, filter, filtrate is concentrated into the thick paste that relative density is 1.20 (55-60 ℃), put cold, add ethanol and make that to contain the alcohol amount be 70%, leave standstill, the leaching supernatant reclaims ethanol, be concentrated into relative density 1.30 (55-60 ℃), with above-mentioned stem and leaf of Radix Ginseng saponin, Rhizoma Dioscoreae is waited until four flavor fine powders, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge, and drying is with the substrate heating and melting, add dry medicated powder, mixing, impouring scribble in the bolt mould of releasing agent, cooling, take out, promptly get suppository.
Embodiment 7
Ginsenoside's 8 weight portion Radixs Astragali 150 weight portion Radix Rehmanniae 250 weight portions
Radix Ophiopogonis 80 weight portion Radix Trichosanthis, 80 weight portion Fructus Lyciis, 80 weight portions
Fructus Schisandrae Chinensis 80 weight portion Rhizoma Dioscoreaes 80 weight portion Fructus Rubies 50 weight portions
Poria 80 weight portion Rhizoma Alismatis 80 weight portions
Soak clearly 2 time with warm water Radix Ophiopogonis, each 1 hour, merge leaching, it is the thick paste of 1.10 (55-60 ℃) that filtrate concentrates the back relative density, Fructus Schisandrae Chinensis 60% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.30 (55-60 ℃) thick paste, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, the Poria water decocts 2 times, each 2 hours, collecting decoction, filter, filtrate is concentrated into the thick paste that relative density is 1.20 (55-60 ℃), put coldly, add ethanol and make that to contain the alcohol amount be 80%, leave standstill, the leaching supernatant, reclaim ethanol, be concentrated into relative density 1.30 (55-60 ℃), with above-mentioned stem and leaf of Radix Ginseng saponin and Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge, and other gets sucrose and makes syrup, merge with above-mentioned extractum, add water system full dose, filter fill, sterilization promptly gets mixture.
Embodiment 8
Ginsenoside's 8 weight portion Radixs Astragali 150 weight portion Radix Rehmanniae 250 weight portions
Radix Ophiopogonis 80 weight portion Radix Trichosanthis, 80 weight portion Fructus Lyciis, 160 weight portions
Fructus Schisandrae Chinensis 40 weight portion Rhizoma Dioscoreaes 80 weight portion Fructus Rubies 50 weight portions
Poria 80 weight portion Rhizoma Alismatis 80 weight portions
With Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, Poria four flavors are ground into fine powder, soak clearly 2 time with warm water Radix Ophiopogonis, each 1.5 hours, merge leaching, it is the thick paste of 1.25 (55-60 ℃) that filtrate concentrates the back relative density, Fructus Schisandrae Chinensis 50% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.30 (55-60 ℃) thick paste, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, the Rhizoma Alismatis water decocts 3 times, and each 1 hour, collecting decoction, filter, filtrate is concentrated into the thick paste that relative density is 1.20 (55-60 ℃), put cold, add ethanol and make that to contain the alcohol amount be 75%, leave standstill, the leaching supernatant reclaims ethanol, be concentrated into relative density 1.30 (55-60 ℃), with above-mentioned stem and leaf of Radix Ginseng saponin, Rhizoma Dioscoreae is waited until four flavor fine powders, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge, and mixing is dried to fine powder, sieve, promptly get powder.
Embodiment 9
Ginsenoside's 8 weight portion Radixs Astragali 150 weight portion Radix Rehmanniae 250 weight portions
Radix Ophiopogonis 80 weight portion Radix Trichosanthis, 80 weight portion Fructus Lyciis, 160 weight portions
Fructus Schisandrae Chinensis 80 weight portion Rhizoma Dioscoreaes 40 weight portion Fructus Rubies 50 weight portions
Poria 80 weight portion Rhizoma Alismatis 80 weight portions
With Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, Poria four flavors are ground into fine powder, soak clearly 1 time with warm water Radix Ophiopogonis, each 2 hours, merge leaching, it is the thick paste of 1.20 (55-60 ℃) that filtrate concentrates the back relative density, Fructus Schisandrae Chinensis 55% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.30 (55-60 ℃) thick paste, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, the Rhizoma Alismatis water decocts 2 times, each 1.5 hours, collecting decoction, filter, filtrate is concentrated into the thick paste that relative density is 1.20 (55-60 ℃), put coldly, add ethanol and make that to contain the alcohol amount be 80%, leave standstill, the leaching supernatant, reclaim ethanol, be concentrated into relative density 1.30 (55-60 ℃), with above-mentioned stem and leaf of Radix Ginseng saponin, Rhizoma Dioscoreae is waited until four flavor fine powders, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge, drying, the system granule, drying, tabletting promptly gets tablet.
Embodiment 10
Ginsenoside's 8 weight portion Radixs Astragali 150 weight portion Radix Rehmanniae 250 weight portions
Radix Ophiopogonis 80 weight portion Radix Trichosanthis, 80 weight portion Fructus Lyciis, 160 weight portions
Fructus Schisandrae Chinensis 80 weight portion Rhizoma Dioscoreaes 80 weight portion Fructus Rubies 20 weight portions
Poria 80 weight portion Rhizoma Alismatis 80 weight portions
With Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, Poria four flavors are ground into fine powder, soak clearly 2 time with warm water Radix Ophiopogonis, each 1.5 hours, merge leaching, it is the thick paste of 1.10 (55-60 ℃) that filtrate concentrates the back relative density, Fructus Schisandrae Chinensis 50% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.30 (55-60 ℃) thick paste, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, the Rhizoma Alismatis water decocts 3 times, each 1 hour, collecting decoction, filter, filtrate is concentrated into the thick paste that relative density is 1.20 (55-60 ℃), put coldly, add ethanol and make that to contain the alcohol amount be 75%, leave standstill, the leaching supernatant, reclaim ethanol, be concentrated into relative density 1.30 (55-60 ℃), with above-mentioned stem and leaf of Radix Ginseng saponin, Rhizoma Dioscoreae is waited until four flavor fine powders, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge, drying, getting the PVA adding distil water soaks, heating for dissolving adds dry extract, stirring and dissolving again, add glycerol again, tween 80, stir evenly, leave standstill and remove bubble, be coated on the glass plate and make film, 80 ℃ of demouldings, be cut into suitable size, sealing promptly gets membrane.
Embodiment 11
Ginsenoside's 8 weight portion Radixs Astragali 150 weight portion Radix Rehmanniae 250 weight portions
Radix Ophiopogonis 80 weight portion Radix Trichosanthis, 80 weight portion Fructus Lyciis, 160 weight portions
Fructus Schisandrae Chinensis 80 weight portion Rhizoma Dioscoreaes 80 weight portion Fructus Rubies 50 weight portions
Poria 40 weight portion Rhizoma Alismatis 80 weight portions
Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, Poria four flavors are ground into fine powder, soak clearly 2 time with warm water Radix Ophiopogonis, each 0.5 hour, merge leaching, it is the thick paste of 1.20 (55-60 ℃) that filtrate concentrates the back relative density, Fructus Schisandrae Chinensis 45% ethanol, percolation, percolate reclaims ethanol, and being concentrated into relative density is 1.30 (55-60 ℃) thick paste, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, the Rhizoma Alismatis water decocts 4 times, each 0.5 hour, collecting decoction, filter, filtrate is concentrated into the thick paste that relative density is 1.20 (55-60 ℃), puts coldly, adds ethanol and makes that to contain the alcohol amount be 65%, leave standstill, the leaching supernatant, reclaim ethanol, be concentrated into relative density 1.30 (55-60 ℃), above-mentioned stem and leaf of Radix Ginseng saponin, Rhizoma Dioscoreae is waited until four flavor fine powders, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge, dry, the taking polyethylene glycol heating and melting adds dry powder, drips and makes ball, packing promptly gets drop pill.
Embodiment 12
Ginsenoside's 8 weight portion Radixs Astragali 150 weight portion Radix Rehmanniae 250 weight portions
Radix Ophiopogonis 80 weight portion Radix Trichosanthis, 80 weight portion Fructus Lyciis, 160 weight portions
Fructus Schisandrae Chinensis 80 weight portion Rhizoma Dioscoreaes 80 weight portion Fructus Rubies 50 weight portions
Poria 80 weight portion Rhizoma Alismatis 40 weight portions.
Soak clearly 1 time with warm water Radix Ophiopogonis, each 3 hours, merges leaching, it is the thick paste of 1.30 (55-60 ℃) that filtrate concentrates the back relative density, Fructus Schisandrae Chinensis 70% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.30 (55-60 ℃) thick paste, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, the Poria water decocts 1 time, 3 hours, collecting decoction, filter, filtrate is concentrated into the thick paste that relative density is 1.20 (55-60 ℃), put coldly, add ethanol and make that to contain the alcohol amount be 80%, leave standstill, the leaching supernatant, reclaim ethanol, be concentrated into relative density 1.30 (55-60 ℃), with above-mentioned Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, extractum such as Poria merge, and add 10 times of water gagings, add stem and leaf of Radix Ginseng saponin, Cryoprecipitation 48 hours filters, and filtrate concentrates, to regulating PH to 8, add 0.1% active carbon, heated and boiled 30 minutes is filtered, add to the full amount of water for injection, filter fine straining, embedding sterilization, check promptly gets injection.
Embodiment 13
Ginsenoside's 2 weight portion Radixs Astragali 250 weight portion Radix Rehmanniae 300 weight portions
Radix Ophiopogonis 120 weight portion Radix Trichosanthis, 120 weight portion Fructus Lyciis, 250 weight portions
Fructus Schisandrae Chinensis 120 weight portion Rhizoma Dioscoreaes 120 weight portion Fructus Rubies 100 weight portions
Poria 150 weight portion Rhizoma Alismatis 120 weight portions.
Soak clearly 2 time with warm water Radix Ophiopogonis, each 2 hours, merges leaching, it is the thick paste of 1.10-1.20 that filtrate concentrates the back relative density, Fructus Schisandrae Chinensis 40% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.30 thick pastes, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, the Poria water decocts 4 times, each 0.5 hour, collecting decoction, filter, it is 1.20 thick paste that filtrate is concentrated into relative density, put coldly, add ethanol and make that to contain the alcohol amount be 70%, leave standstill, the leaching supernatant, reclaim ethanol, be concentrated into relative density 1.30, with above-mentioned Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, extractum such as Rhizoma Dioscoreae merge, and get that stem and leaf of Radix Ginseng saponin is dissolved in water and extractum merges, add 10 times of water gagings, Cryoprecipitation 48 hours filters, and filtrate concentrates, to regulating PH to 7.5, add 0.1% active carbon, heated and boiled 30 minutes is filtered, add to the full amount of water for injection, filter, fine straining, lyophilization is aseptic subpackaged, check promptly gets the powder pin.
Embodiment 14
Ginsenoside's 15 weight portion Radixs Astragali 40 weight portion Radix Rehmanniae 300 weight portions
Radix Ophiopogonis 120 weight portion Radix Trichosanthis, 120 weight portion Fructus Lyciis, 250 weight portions
Fructus Schisandrae Chinensis 120 weight portion Rhizoma Dioscoreaes 120 weight portion Fructus Rubies 100 weight portions
Poria 150 weight portion Rhizoma Alismatis 120 weight portions.
Soak clearly 3 time with warm water Radix Ophiopogonis, each 0.5 hour, merges leaching, it is the thick paste of 1.20-1.30 that filtrate concentrates the back relative density, Fructus Schisandrae Chinensis 50% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.30 thick pastes, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, the Poria water decocts 2 times, and each 1.5 hours, collecting decoction, filter, it is 1.20 thick paste that filtrate is concentrated into relative density, put cold, add ethanol and make that to contain the alcohol amount be 75%, leave standstill, the leaching supernatant reclaims ethanol, be concentrated into relative density 1.30, with above-mentioned Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, extractum such as Rhizoma Dioscoreae merge, and get that stem and leaf of Radix Ginseng saponin is dissolved in water and extractum merges, and add 10 times of water gagings, Cryoprecipitation 48 hours, filter, filtrate concentrates, to regulating PH to 7, add 0.1% active carbon, heated and boiled 30 minutes is filtered, and adds to the full amount of water for injection, filter, fine straining, the embedding sterilizing test promptly gets and infuses.
Embodiment 15
Ginsenoside's 15 weight portion Radixs Astragali 250 weight portion Radix Rehmanniae 80 weight portions
Radix Ophiopogonis 120 weight portion Radix Trichosanthis, 120 weight portion Fructus Lyciis, 250 weight portions
Fructus Schisandrae Chinensis 120 weight portion Rhizoma Dioscoreaes 120 weight portion Fructus Rubies 100 weight portions
Poria 150 weight portion Rhizoma Alismatis 120 weight portions.
Soak clearly 2 time with warm water Radix Ophiopogonis, each 2.5 hours, merge leaching, relative density was 1.15 thick paste after filtrate concentrated, Fructus Schisandrae Chinensis 60% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.30 thick pastes, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, the Poria water decocts 3 times, and each 1 hour, collecting decoction, filter, it is 1.20 thick paste that filtrate is concentrated into relative density, put cold, add ethanol and make that to contain the alcohol amount be 60%, leave standstill, the leaching supernatant reclaims ethanol, be concentrated into relative density 1.30, with above-mentioned Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, extractum such as Rhizoma Dioscoreae merge, and the stem and leaf of Radix Ginseng saponin dissolve with ethanol merges, the ethanol that adds normal concentration, stir, filter, promptly get tincture.
Embodiment 16
Ginsenoside's 15 weight portion Radixs Astragali 250 weight portion Radix Rehmanniae 300 weight portions
Radix Ophiopogonis 20 weight portion Radix Trichosanthis, 120 weight portion Fructus Lyciis, 250 weight portions
Fructus Schisandrae Chinensis 120 weight portion Rhizoma Dioscoreaes 120 weight portion Fructus Rubies 100 weight portions
Poria 150 weight portion Rhizoma Alismatis 120 weight portions.
Soak clearly 2 time with warm water Radix Ophiopogonis, each 2 hours, merge leaching, relative density was 1.18 thick paste after filtrate concentrated, Fructus Schisandrae Chinensis 50% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.30 thick pastes, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, the Poria water decocts 2 times, and each 1.5 hours, collecting decoction, filter, it is 1.20 thick paste that filtrate is concentrated into relative density, put cold, add ethanol and make that to contain the alcohol amount be 50%, leave standstill, the leaching supernatant reclaims ethanol, be concentrated into relative density 1.30, with above-mentioned stem and leaf of Radix Ginseng saponin and Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, extractum such as Rhizoma Dioscoreae merge, and other gets sucrose and adds an amount of heated and boiled of water, dissolving, filter, concentrate and make syrup,, boil with above-mentioned concentrated solution mixing, put cold, add antiseptic and essence, thin up promptly gets syrup.
Embodiment 17
Ginsenoside's 15 weight portion Radixs Astragali 250 weight portion Radix Rehmanniae 300 weight portions
Radix Ophiopogonis 120 weight portion Radix Trichosanthis, 20 weight portion Fructus Lyciis, 250 weight portions
Fructus Schisandrae Chinensis 120 weight portion Rhizoma Dioscoreaes 120 weight portion Fructus Rubies 100 weight portions
Poria 150 weight portion Rhizoma Alismatis 120 weight portions.
Soak clearly 2 time with warm water Radix Ophiopogonis, each 1 hour, merge leaching, relative density was 1.1 thick paste after filtrate concentrated, Fructus Schisandrae Chinensis 55% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.10 thick pastes, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, the Poria water decocts 3 times, each 0.5 hour, collecting decoction, filter, it is 1.20 thick paste that filtrate is concentrated into relative density, put coldly, add ethanol and make that to contain the alcohol amount be 40%, leave standstill, the leaching supernatant, reclaim ethanol, be concentrated into relative density 1.10, with above-mentioned stem and leaf of Radix Ginseng saponin and Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, extractum such as Rhizoma Dioscoreae merge, and other gets sucrose and makes syrup, merge with above-mentioned medicinal liquid, add water system full dose, filter fill, sterilization promptly gets mixture.
Embodiment 18
Ginsenoside's 15 weight portion Radixs Astragali 250 weight portion Radix Rehmanniae 300 weight portions
Radix Ophiopogonis 120 weight portion Radix Trichosanthis, 120 weight portion Fructus Lyciis, 40 weight portions
Fructus Schisandrae Chinensis 120 weight portion Rhizoma Dioscoreaes 120 weight portion Fructus Rubies 100 weight portions
Poria 150 weight portion Rhizoma Alismatis 120 weight portions.
With Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, Poria four flavors are ground into fine powder, soak clearly 2 time with warm water Radix Ophiopogonis, each 1.5 hours, merge leaching, relative density was 1.10 thick paste after filtrate concentrated, Fructus Schisandrae Chinensis 40-70% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.10 thick pastes, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, the Rhizoma Alismatis water decocts 2 times, each 2.5 hours, collecting decoction, filter, it is 1.20 thick paste that filtrate is concentrated into relative density, put coldly, add ethanol and make that to contain the alcohol amount be 55%, leave standstill, the leaching supernatant, reclaim ethanol, be concentrated into relative density 1.10, with above-mentioned stem and leaf of Radix Ginseng saponin, Rhizoma Dioscoreae is waited until four flavor fine powders, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge, mixing, it is an amount of to add PVC, granulate, dry granulate, packing is promptly.
Assay method is:
(1) ginsenoside Re's assay method is:
The preparation of reference substance solution: it is an amount of that precision takes by weighing ginsenoside Re's reference substance, adds methanol and make the solution that contains ginsenoside Re 0.4mg among every 1ml respectively, in contrast product solution;
The preparation of need testing solution: get this product, grind well, precision takes by weighing about 1 gram, add chloroform 20ml, water-bath refluxed 1 hour, filtered, discard chloroform, residue volatilizes solvent, and residue places same tool match conical flask together with filter paper, adds the saturated water 2ml moistening of n-butyl alcohol, the accurate adding with water-saturated n-butanol 50ml supersound extraction 30min, precision is measured supernatant 25ml, adds the ammonia solution triplication, shakes up, place, divide and get upper solution, evaporate to dryness, residue add methanol makes dissolving, quantitatively move in the 2ml measuring bottle, add methanol and be diluted to scale, shake up, promptly;
Chromatographic condition: with octadecylsilane chemically bonded silica is filler;
Volume ratio is that 99: 400 acetonitrile-0.05% phosphoric acid solution is a mobile phase; Detect wavelength 203nm; Algoscopy: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject the every gram granule of hplc determination and contain ginsenoside Re 5.0mg.
(2) assay method of astragaloside is:
Chromatographic condition: octadecylsilane chemically bonded silica is a filler; Evaporative light scattering detector;
Mobile phase: ratio is acetonitrile-water-oxolane of 33: 67: 4;
The preparation of reference substance solution: get the astragaloside reference substance and add methanol and make the solution that every 1ml contains 0.6mg, shake up, promptly;
The preparation of need testing solution: get this product, grind well, precision takes by weighing about 10 grams, add water 50ml dissolving, filter, filtrate is used defat with petroleum ether 2 times, (each 50ml) extracted in water saturated n-butyl alcohol jolting 4 times, merges n-butanol extracting liquid, extracts 2 times with ammonia solution, each 40ml discards ammonia solution, and the water 40ml saturated with n-butyl alcohol washes, discard water liquid, n-butyl alcohol liquid evaporate to dryness, residue add water 10mL makes dissolving, put coldly, pass through D
101Type macroporous adsorptive resins (interior through 1.5cm, long 18cm) is with water 100mL eluting, discard water liquid, reuse 40% ethanol 50ml eluting discards 40% ethanol elution, continue with 70% ethanol 100ml eluting, collect eluent, evaporate to dryness is with dissolve with methanol and be transferred in the 2ml measuring bottle, add methanol to scale, shake up, filter, promptly.
Algoscopy: accurate respectively reference substance solution 5 μ l, the 10 μ l of drawing, each 20 μ l of need testing solution inject hplc determination
Every gram granule contains astragaloside 0.08mg.
Embodiment 19
Ginsenoside's 15 weight portion Radixs Astragali 250 weight portion Radix Rehmanniae 300 weight portions
Radix Ophiopogonis 120 weight portion Radix Trichosanthis, 120 weight portion Fructus Lyciis, 250 weight portions
Fructus Schisandrae Chinensis 20 weight portion Rhizoma Dioscoreaes 120 weight portion Fructus Rubies 100 weight portions
Poria 150 weight portion Rhizoma Alismatis 120 weight portions.
With Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, Poria four flavors are ground into fine powder, soak clearly 2 time with warm water Radix Ophiopogonis, each 1.5 hours, merge leaching, relative density was 1.10 thick paste after filtrate concentrated, Fructus Schisandrae Chinensis 40-70% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.10 thick pastes, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, the Rhizoma Alismatis water decocts 2 times, each 2.5 hours, collecting decoction, filter, it is 1.20 thick paste that filtrate is concentrated into relative density, put coldly, add ethanol and make that to contain the alcohol amount be 55%, leave standstill, the leaching supernatant, reclaim ethanol, be concentrated into relative density 1.10, with above-mentioned stem and leaf of Radix Ginseng saponin, Rhizoma Dioscoreae is waited until four flavor fine powders, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge, mixing, it is an amount of to add methylcellulose, granulate, dry granulate, packing is promptly.
Assay method is:
(1) ginsenoside Re's assay method is:
The preparation of reference substance solution: it is an amount of that precision takes by weighing ginsenoside Re's reference substance, adds methanol and make the solution that contains ginsenoside Re 0.4mg among every 1ml respectively, in contrast product solution;
The preparation of need testing solution: get this product, grind well, precision takes by weighing about 1 gram, add chloroform 20ml, water-bath refluxed 1 hour, filtered, discard chloroform, residue volatilizes solvent, and residue places same tool match conical flask together with filter paper, adds the saturated water 2ml moistening of n-butyl alcohol, the accurate adding with water-saturated n-butanol 50ml supersound extraction 30min, precision is measured supernatant 25ml, adds the ammonia solution triplication, shakes up, place, divide and get upper solution, evaporate to dryness, residue add methanol makes dissolving, quantitatively move in the 2ml measuring bottle, add methanol and be diluted to scale, shake up, promptly;
Chromatographic condition: with octadecylsilane chemically bonded silica is filler;
Volume ratio is that 99: 400 acetonitrile-0.05% phosphoric acid solution is a mobile phase; Detect wavelength 203nm; Algoscopy: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject the every gram granule of hplc determination and contain ginsenoside Re 0.5mg.
(2) assay method of astragaloside is:
Chromatographic condition: octadecylsilane chemically bonded silica is a filler; Evaporative light scattering detector;
Mobile phase: ratio is acetonitrile-water-oxolane of 33: 67: 4;
The preparation of reference substance solution: get the astragaloside reference substance and add methanol and make the solution that every 1ml contains 0.6mg, shake up, promptly;
The preparation of need testing solution: get this product, grind well, precision takes by weighing about 10 grams,, add water 50ml dissolving, filter, filtrate is used defat with petroleum ether 2 times, and (each 50ml) extracted in water saturated n-butyl alcohol jolting 4 times, merges n-butanol extracting liquid, extract 2 times with ammonia solution, each 40ml discards ammonia solution, the water 40ml saturated with n-butyl alcohol washes, and discards water liquid, n-butyl alcohol liquid evaporate to dryness, residue adds water 10mL makes dissolving, puts coldly, passes through D
101Type macroporous adsorptive resins (interior through 1.5cm, long 18cm) is with water 100mL eluting, discard water liquid, reuse 40% ethanol 50ml eluting discards 40% ethanol elution, continue with 70% ethanol 100ml eluting, collect eluent, evaporate to dryness is with dissolve with methanol and be transferred in the 2ml measuring bottle, add methanol to scale, shake up, filter, promptly.
Algoscopy: accurate respectively reference substance solution 5 μ l, the 10 μ l of drawing, each 20 μ l of need testing solution inject hplc determination
Every gram granule contains astragaloside 0.04mg.
Embodiment 20
Ginsenoside's 15 weight portion Radixs Astragali 250 weight portion Radix Rehmanniae 300 weight portions
Radix Ophiopogonis 120 weight portion Radix Trichosanthis, 120 weight portion Fructus Lyciis, 250 weight portions
Fructus Schisandrae Chinensis 120 weight portion Rhizoma Dioscoreaes 20 weight portion Fructus Rubies 100 weight portions
Poria 150 weight portion Rhizoma Alismatis 120 weight portions.
With Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, Poria four flavors are ground into fine powder, soak clearly 2 time with warm water Radix Ophiopogonis, each 1.5 hours, merge leaching, relative density was 1.10 thick paste after filtrate concentrated, Fructus Schisandrae Chinensis 40-70% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.10 thick pastes, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, the Rhizoma Alismatis water decocts 2 times, each 2.5 hours, collecting decoction, filter, it is 1.20 thick paste that filtrate is concentrated into relative density, put coldly, add ethanol and make that to contain the alcohol amount be 55%, leave standstill, the leaching supernatant, reclaim ethanol, be concentrated into relative density 1.10, with above-mentioned stem and leaf of Radix Ginseng saponin, Rhizoma Dioscoreae is waited until four flavor fine powders, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge, mixing, it is an amount of to add arabic gum, granulate, dry granulate, packing is promptly.
Embodiment 21
Ginsenoside's 15 weight portion Radixs Astragali 250 weight portion Radix Rehmanniae 300 weight portions
Radix Ophiopogonis 120 weight portion Radix Trichosanthis, 120 weight portion Fructus Lyciis, 250 weight portions
Fructus Schisandrae Chinensis 120 weight portion Rhizoma Dioscoreaes 120 weight portion Fructus Rubies 15 weight portions
Poria 150 weight portion Rhizoma Alismatis 120 weight portions.
With Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, Poria four flavors are ground into fine powder, soak clearly 2 time with warm water Radix Ophiopogonis, each 1.5 hours, merge leaching, relative density was 1.10 thick paste after filtrate concentrated, Fructus Schisandrae Chinensis 40-70% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.10 thick pastes, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, the Rhizoma Alismatis water decocts 2 times, each 2.5 hours, collecting decoction, filter, it is 1.20 thick paste that filtrate is concentrated into relative density, put coldly, add ethanol and make that to contain the alcohol amount be 55%, leave standstill, the leaching supernatant, reclaim ethanol, be concentrated into relative density 1.10, with above-mentioned stem and leaf of Radix Ginseng saponin, Rhizoma Dioscoreae is waited until four flavor fine powders, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge, mixing, it is an amount of to add tragacanth, granulate, dry granulate, packing is promptly.
Embodiment 22
Ginsenoside's 15 weight portion Radixs Astragali 250 weight portion Radix Rehmanniae 300 weight portions
Radix Ophiopogonis 120 weight portion Radix Trichosanthis, 120 weight portion Fructus Lyciis, 250 weight portions
Fructus Schisandrae Chinensis 120 weight portion Rhizoma Dioscoreaes 120 weight portion Fructus Rubies 100 weight portions
Poria 20 weight portion Rhizoma Alismatis 120 weight portions.
With Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, Poria four flavors are ground into fine powder, soak clearly 2 time with warm water Radix Ophiopogonis, each 1.5 hours, merge leaching, relative density was 1.10 thick paste after filtrate concentrated, Fructus Schisandrae Chinensis 40-70% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.10 thick pastes, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, the Rhizoma Alismatis water decocts 2 times, each 2.5 hours, collecting decoction, filter, it is 1.20 thick paste that filtrate is concentrated into relative density, put coldly, add ethanol and make that to contain the alcohol amount be 55%, leave standstill, the leaching supernatant, reclaim ethanol, be concentrated into relative density 1.10, with above-mentioned stem and leaf of Radix Ginseng saponin, Rhizoma Dioscoreae is waited until four flavor fine powders, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge, mixing, it is an amount of to add sodium alginate or potassium alginate, granulate, dry granulate, packing is promptly.
Embodiment 23
Ginsenoside's 15 weight portion Radixs Astragali 250 weight portion Radix Rehmanniae 300 weight portions
Radix Ophiopogonis 120 weight portion Radix Trichosanthis, 120 weight portion Fructus Lyciis, 250 weight portions
Fructus Schisandrae Chinensis 120 weight portion Rhizoma Dioscoreaes 120 weight portion Fructus Rubies 100 weight portions
Poria 150 weight portion Rhizoma Alismatis 20 weight portions.
With Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, Poria four flavors are ground into fine powder, soak clearly 2 time with warm water Radix Ophiopogonis, each 1.5 hours, merge leaching, relative density was 1.10 thick paste after filtrate concentrated, Fructus Schisandrae Chinensis 40-70% ethanol, percolation, percolate reclaims ethanol, being concentrated into relative density is 1.10 thick pastes, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, the Rhizoma Alismatis water decocts 2 times, each 2.5 hours, collecting decoction, filter, it is 1.20 thick paste that filtrate is concentrated into relative density, put coldly, add ethanol and make that to contain the alcohol amount be 55%, leave standstill, the leaching supernatant, reclaim ethanol, be concentrated into relative density 1.10, with above-mentioned stem and leaf of Radix Ginseng saponin, Rhizoma Dioscoreae is waited until four flavor fine powders, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge, mixing, it is an amount of to add dextrin, granulate, dry granulate, packing is promptly.
Assay method is:
(1) ginsenoside Re's assay method is:
The preparation of reference substance solution: it is an amount of that precision takes by weighing ginsenoside Re's reference substance, adds methanol and make the solution that contains ginsenoside Re 0.4mg among every 1ml respectively, in contrast product solution;
The preparation of need testing solution: get this product, grind well, precision takes by weighing about 1 gram, add chloroform 20ml, water-bath refluxed 1 hour, filtered, discard chloroform, residue volatilizes solvent, and residue places same tool match conical flask together with filter paper, adds the saturated water 2ml moistening of n-butyl alcohol, the accurate adding with water-saturated n-butanol 50ml supersound extraction 30min, precision is measured supernatant 25ml, adds the ammonia solution triplication, shakes up, place, divide and get upper solution, evaporate to dryness, residue add methanol makes dissolving, quantitatively move in the 2ml measuring bottle, add methanol and be diluted to scale, shake up, promptly;
Chromatographic condition: with octadecylsilane chemically bonded silica is filler;
Volume ratio is that 99: 400 acetonitrile-0.05% phosphoric acid solution is a mobile phase; Detect wavelength 203nm; Algoscopy: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject the every gram granule of hplc determination and contain ginsenoside Re 10mg.
(2) assay method of astragaloside is:
Chromatographic condition: octadecylsilane chemically bonded silica is a filler; Evaporative light scattering detector;
Mobile phase: ratio is acetonitrile-water-oxolane of 33: 67: 4;
The preparation of reference substance solution: get the astragaloside reference substance and add methanol and make the solution that every 1ml contains 0.6mg, shake up, promptly;
The preparation of need testing solution: get this product, grind well, precision takes by weighing about 10 grams, add water 50ml dissolving, filter, filtrate is used defat with petroleum ether 2 times, (each 50ml) extracted in water saturated n-butyl alcohol jolting 4 times, merges n-butanol extracting liquid, extracts 2 times with ammonia solution, each 40ml discards ammonia solution, and the water 40ml saturated with n-butyl alcohol washes, discard water liquid, n-butyl alcohol liquid evaporate to dryness, residue add water 10mL makes dissolving, put coldly, pass through D
101Type macroporous adsorptive resins (interior through 1.5cm, long 18cm) is with water 100mL eluting, discard water liquid, reuse 40% ethanol 50ml eluting discards 40% ethanol elution, continue with 70% ethanol 100ml eluting, collect eluent, evaporate to dryness is with dissolve with methanol and be transferred in the 2ml measuring bottle, add methanol to scale, shake up, filter, promptly.
Algoscopy: accurate respectively reference substance solution 5 μ l, the 10 μ l of drawing, each 20 μ l of need testing solution inject hplc determination
Every gram granule contains astragaloside 0.5mg.
Claims (10)
1, a kind of Chinese medicine composition for the treatment of diabetes is characterized in that it is formed by following feedstock production:
Ginsenoside 4-8 weight portion Radix Astragali 80-150 weight portion Radix Rehmanniae 150-250 weight portion
Radix Ophiopogonis 45-80 weight portion Radix Trichosanthis 40-80 weight portion Fructus Lycii 80-160 weight portion
Fructus Schisandrae Chinensis 40-80 weight portion Rhizoma Dioscoreae 40-80 weight portion Fructus Rubi 20-50 weight portion
Poria 40-80 weight portion Rhizoma Alismatis 40-80 weight portion.
2, Chinese medicine composition as claimed in claim 1 is characterized in that each proportion of raw materials is:
Ginsenoside's 6 weight portion Radixs Astragali 124 weight portion Radix Rehmanniae 186 weight portions
Radix Ophiopogonis 62 weight portion Radix Trichosanthis, 62 weight portion Fructus Lyciis, 124 weight portions
Fructus Schisandrae Chinensis 62 weight portion Rhizoma Dioscoreaes 62 weight portion Fructus Rubies 31 weight portions
Poria 62 weight portion Rhizoma Alismatis 62 weight portions.
3,, it is characterized in that this pharmaceutical composition adds excipient and makes clinical acceptable various dosage forms as stating compositions as described in claim 1 or 2.
4, Chinese medicine composition as claimed in claim 3 is characterized in that its dosage form is preferably granule.
5, preparation as claimed in claim 4 is characterized in that every gram granule contains ginsenoside Re 0.1-10mg.
6, preparation as claimed in claim 4 is characterized in that every gram granule contains astragaloside 0.02-0.5mg.
7,, it is characterized in that assay method is as claim 5 or 6 described effective ingredient:
(1) ginsenoside Re's assay method is:
The preparation of reference substance solution: it is an amount of that precision takes by weighing ginsenoside Re's reference substance, adds methanol and make the solution that contains ginsenoside Re 0.4mg among every 1ml respectively, in contrast product solution;
The preparation of need testing solution: get this product, grind well, precision takes by weighing about 1 gram, add chloroform 20ml, water-bath refluxed 1 hour, filtered, discard chloroform, residue volatilizes solvent, and residue places same tool match conical flask together with filter paper, adds the saturated water 2ml moistening of n-butyl alcohol, the accurate adding with water-saturated n-butanol 50ml supersound extraction 30min, precision is measured supernatant 25ml, adds the ammonia solution triplication, shakes up, place, divide and get upper solution, evaporate to dryness, residue add methanol makes dissolving, quantitatively move in the 2ml measuring bottle, add methanol and be diluted to scale, shake up, promptly;
Chromatographic condition: with octadecylsilane chemically bonded silica is filler;
Volume ratio is that 99: 400 acetonitrile-0.05% phosphoric acid solution is a mobile phase; Detect wavelength 203nm; Algoscopy: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject hplc determination;
(2) assay method of astragaloside is:
Chromatographic condition: octadecylsilane chemically bonded silica is a filler; Evaporative light scattering detector;
Mobile phase: ratio is acetonitrile-water-oxolane of 33: 67: 4;
The preparation of reference substance solution: get the astragaloside reference substance and add methanol and make the solution that every 1ml contains 0.6mg, shake up, promptly;
The preparation of need testing solution: get this product, grind well, precision takes by weighing about 10 grams, add water 50ml dissolving, filter, filtrate is used defat with petroleum ether 2 times, (each 50ml) extracted in water saturated n-butyl alcohol jolting 4 times, merges n-butanol extracting liquid, extracts 2 times with ammonia solution, each 40ml discards ammonia solution, and the water 40ml saturated with n-butyl alcohol washes, discard water liquid, n-butyl alcohol liquid evaporate to dryness, residue add water 10mL makes dissolving, put coldly, pass through D
101Type macroporous adsorptive resins (interior through 1.5cm, long 18cm) is with water 100mL eluting, discard water liquid, reuse 40% ethanol 50ml eluting discards 40% ethanol elution, continue with 70% ethanol 100ml eluting, collect eluent, evaporate to dryness is with dissolve with methanol and be transferred in the 2ml measuring bottle, add methanol to scale, shake up, filter, promptly.
8, Chinese medicine composition as claimed in claim 5, it is characterized in that its preparation method is: with Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, Poria four flavors are ground into fine powder, use warm water lixiviate 1-3 time Radix Ophiopogonis, each 0.5-3 hour, merge lixiviating solution, filter, filtrate is concentrated into the thick paste that relative density is 1.03-1.40, Fructus Schisandrae Chinensis 40-70% ethanol percolation, percolate reclaims ethanol, be concentrated into relative density and be about the 1.10-1.40 thick paste, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, the Rhizoma Alismatis water decocts 1-4 time, each 0.5-3 hour, merge decoction liquor, filter, it is 1.20 thick paste that filtrate is concentrated into relative density, puts cold, adding ethanol makes and contains the alcohol amount and be 40%-80%, leave standstill, the leaching supernatant reclaims ethanol, is concentrated into relative density 1.1-1.40, with above-mentioned stem and leaf of Radix Ginseng saponin, Rhizoma Dioscoreae is waited until four flavor fine powders, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, extractum such as Rhizoma Alismatis merge or are dry, add medicinal adjuvant routinely preparation process make clinical required dosage form.
9, preparation method as claimed in claim 8 also adds suspending agent as ethylhydroxyethylcellulose, chitin, methylcellulose, tragacanth, arabic gum, sodium alginate, potassium alginate, calcium alginate, hydroxyethyl-cellulose, hydroxypropyl cellulose, dextrin among it is characterized in that.
10, preparation method as claimed in claim 9 can replace with purgation: use warm water lixiviate 1-3 time Radix Ophiopogonis, each 0.5-3 hour, merge lixiviating solution, filter, filtrate is concentrated into the thick paste that relative density is 1.03-1.40, Fructus Schisandrae Chinensis 40-70% ethanol, percolation, percolate reclaims ethanol, be concentrated into thick paste, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, Rhizoma Dioscoreae, Radix Trichosanthis, Fructus Rubi, the Poria water decocts 1-4 time, each 0.5-3 hour, merge decoction liquor, filter, it is 1.20 thick paste that filtrate is concentrated into relative density, put coldly, add ethanol and make and contain the alcohol amount and be 40%-80%, leave standstill, the leaching supernatant, reclaim ethanol, concentrate, with above-mentioned Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Lycii, the Radix Astragali, Radix Rehmanniae, Rhizoma Alismatis, extractum ginsenosides such as Rhizoma Dioscoreae merge or drying after again with the ginsenoside, add medicinal adjuvant routinely preparation process make clinical required dosage form.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410073959 CN1245198C (en) | 2004-09-17 | 2004-09-17 | Chinese medicine composition for treating diabetes and its preparing method |
| HK05108659A HK1076721A1 (en) | 2004-09-17 | 2005-09-29 | A chinese traditional medical composition for treating diabetes and method for preparing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410073959 CN1245198C (en) | 2004-09-17 | 2004-09-17 | Chinese medicine composition for treating diabetes and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1616014A true CN1616014A (en) | 2005-05-18 |
| CN1245198C CN1245198C (en) | 2006-03-15 |
Family
ID=34765344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410073959 Active CN1245198C (en) | 2004-09-17 | 2004-09-17 | Chinese medicine composition for treating diabetes and its preparing method |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN1245198C (en) |
| HK (1) | HK1076721A1 (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100333771C (en) * | 2005-07-06 | 2007-08-29 | 鲁南制药集团股份有限公司 | Ginseng and astragalis blood glucose loucring dorpping pill, and its preparing and detecting method |
| CN100341492C (en) * | 2005-07-06 | 2007-10-10 | 鲁南制药集团股份有限公司 | Ginseng-astragalus blood-sugar lowering soft capsule, and its preparing and detecting method |
| CN100341490C (en) * | 2005-07-06 | 2007-10-10 | 鲁南制药集团股份有限公司 | Ginseng and astragalis blood glucose lowering dispersion tablet and its preparing and detecting method |
| CN101862413A (en) * | 2010-07-09 | 2010-10-20 | 喇孝瑾 | Chinese medicinal preparation for treating type-2 diabetes and preparation method thereof |
| CN104109596A (en) * | 2014-07-09 | 2014-10-22 | 徐昕然 | Health-care red wine and preparation method thereof |
| CN104435836A (en) * | 2014-11-22 | 2015-03-25 | 李任 | Traditional Chinese medicine for treating diabetes |
| CN106038926A (en) * | 2016-08-16 | 2016-10-26 | 汪培杰 | Traditional Chinese medicine for treating diabetes and preparation method thereof |
| CN106266543A (en) * | 2016-09-10 | 2017-01-04 | 四川金堂海纳生物医药技术研究所 | A kind of Chinese medicine composition treating type Ⅱdiabetes mellitus and preparation method thereof |
| CN106344789A (en) * | 2016-08-29 | 2017-01-25 | 河南羚锐制药股份有限公司 | Production method of capsule made from traditional Chinese medicine for curing Type-IIdiabetes |
| CN108159258A (en) * | 2018-02-27 | 2018-06-15 | 柯金狮 | Treatment is with Chinese medicine for treating diabetes composition of lumbar vertebra disease and preparation method thereof |
| CN108159233A (en) * | 2018-02-27 | 2018-06-15 | 柯金狮 | A kind of Chinese medicine composition for treating diabetes and preparation method thereof |
| CN113144109A (en) * | 2021-03-20 | 2021-07-23 | 鲁南厚普制药有限公司 | Traditional Chinese medicine composition for treating type II diabetes and preparation method thereof |
| CN114848602A (en) * | 2022-04-18 | 2022-08-05 | 广东万年青制药股份有限公司 | Astragalus membranaceus composite blood sugar reducing buccal tablet and preparation method thereof |
-
2004
- 2004-09-17 CN CN 200410073959 patent/CN1245198C/en active Active
-
2005
- 2005-09-29 HK HK05108659A patent/HK1076721A1/en unknown
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100333771C (en) * | 2005-07-06 | 2007-08-29 | 鲁南制药集团股份有限公司 | Ginseng and astragalis blood glucose loucring dorpping pill, and its preparing and detecting method |
| CN100341492C (en) * | 2005-07-06 | 2007-10-10 | 鲁南制药集团股份有限公司 | Ginseng-astragalus blood-sugar lowering soft capsule, and its preparing and detecting method |
| CN100341490C (en) * | 2005-07-06 | 2007-10-10 | 鲁南制药集团股份有限公司 | Ginseng and astragalis blood glucose lowering dispersion tablet and its preparing and detecting method |
| CN101862413A (en) * | 2010-07-09 | 2010-10-20 | 喇孝瑾 | Chinese medicinal preparation for treating type-2 diabetes and preparation method thereof |
| CN104109596A (en) * | 2014-07-09 | 2014-10-22 | 徐昕然 | Health-care red wine and preparation method thereof |
| CN104435836A (en) * | 2014-11-22 | 2015-03-25 | 李任 | Traditional Chinese medicine for treating diabetes |
| CN106038926A (en) * | 2016-08-16 | 2016-10-26 | 汪培杰 | Traditional Chinese medicine for treating diabetes and preparation method thereof |
| CN106344789A (en) * | 2016-08-29 | 2017-01-25 | 河南羚锐制药股份有限公司 | Production method of capsule made from traditional Chinese medicine for curing Type-IIdiabetes |
| CN106266543A (en) * | 2016-09-10 | 2017-01-04 | 四川金堂海纳生物医药技术研究所 | A kind of Chinese medicine composition treating type Ⅱdiabetes mellitus and preparation method thereof |
| CN108159258A (en) * | 2018-02-27 | 2018-06-15 | 柯金狮 | Treatment is with Chinese medicine for treating diabetes composition of lumbar vertebra disease and preparation method thereof |
| CN108159233A (en) * | 2018-02-27 | 2018-06-15 | 柯金狮 | A kind of Chinese medicine composition for treating diabetes and preparation method thereof |
| CN113144109A (en) * | 2021-03-20 | 2021-07-23 | 鲁南厚普制药有限公司 | Traditional Chinese medicine composition for treating type II diabetes and preparation method thereof |
| CN114848602A (en) * | 2022-04-18 | 2022-08-05 | 广东万年青制药股份有限公司 | Astragalus membranaceus composite blood sugar reducing buccal tablet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1076721A1 (en) | 2006-01-27 |
| CN1245198C (en) | 2006-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1954840A (en) | Medical composite prepared by Gynostemma pentaphylla, American ginseng and astragalus root | |
| CN100349598C (en) | Medicine for treating high lipemia and its production method | |
| CN1748765A (en) | Composition with catharsis and toxin expelling, fat reducing and weight reducing function and preparing method | |
| CN1245198C (en) | Chinese medicine composition for treating diabetes and its preparing method | |
| CN1569156A (en) | Medicament for treating cardiovascular and cerebrovascular disease and its preparation method and quality control method | |
| CN101062084A (en) | Anti-hepatitis medical combination | |
| CN1931236A (en) | Medicine composition of red sage and rhodiola root | |
| CN101049324A (en) | Composition of medication prepared from ginkgo leaves and puerarin | |
| CN1923241A (en) | Medicine composition containing epimedium extract, uncaria extract, and gastrodine, and its preparation and use | |
| CN100341492C (en) | Ginseng-astragalus blood-sugar lowering soft capsule, and its preparing and detecting method | |
| CN1947747A (en) | Traditional Chinese medicine composition contg. luteolin and capsule of sweeping forsythia and its prepn. method and use | |
| CN1954849A (en) | Antineoplastic medical composite compatibility with oldenlandia, ginseng and astragalus root | |
| CN101041004A (en) | Novel antineoplastic compound medicine | |
| CN1294936C (en) | Medicine for treating diabetes and its preparation method | |
| CN1931233A (en) | Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases | |
| CN100341490C (en) | Ginseng and astragalis blood glucose lowering dispersion tablet and its preparing and detecting method | |
| CN1947749A (en) | Medicine composition contg. Poria cocos and Touhualiao (polygonaceae) | |
| CN1954838A (en) | Medical composite of antineoplastic | |
| CN1954870A (en) | Medical composite prepared by sarcandra and oldenlandia | |
| CN1517326A (en) | Capejasmine cycloolefines ether terpene extract and its preparation method and use | |
| CN101040886A (en) | Medicine compound of erigeron breviscapus and tanshinone IIA sodium sulfoacid | |
| CN1616058A (en) | Chinese medicine compound rheumatism preparation for improving bioavailability and medicine effect and preparing method | |
| CN1709439A (en) | Ginseng and astragalis blood glucose loucring dorpping pill, and its preparing and detecting method | |
| CN1947765A (en) | Traditional Chinese medicine composition contg. isatis root and rhizoma belamcandae, and its prepn. method and use | |
| CN1579485A (en) | Traditional Chinese medicinal composition for treating intestinal function disorder and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1076721 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Lunan Pharmaceutical Co., Ltd. Assignor: Lunan Pharmaceutical Group Co., Ltd. Contract record no.: 2010370000516 Denomination of invention: A Chinese traditional medicinal composition for treating diabetes and its preparation method Granted publication date: 20060315 License type: Exclusive License Open date: 20050518 Record date: 20100909 |
|
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Lunan Pharmaceutical Co., Ltd. Assignor: Lunan Pharmaceutical Group Co., Ltd. Contract record no.: 2010370000516 Date of cancellation: 20131016 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20050518 Assignee: Lunan Pharmaceutical Co., Ltd. Assignor: Lunan Pharmaceutical Group Co., Ltd. Contract record no.: 2013370000262 Denomination of invention: A Chinese traditional medicinal composition for treating diabetes and its preparation method Granted publication date: 20060315 License type: Exclusive License Record date: 20131210 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161223 Address after: 276005 Hongqi Road, Shandong, Linyi, No. 209 Patentee after: Lunan Hope Pharmaceutical Co., Ltd. Address before: 276005 Hongqi Road, Shandong, Linyi, No. 209 Patentee before: Lunan Pharmaceutical Group Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220121 Address after: 276006 No. 209 Hongqi Road, Shandong, Linyi Patentee after: LUNAN PHARMACEUTICAL Group Corp. Address before: 276005 No. 209 Hongqi Road, Shandong, Linyi Patentee before: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |